Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an exclusive global license for opevesostat (MK-5684/ODM-208) and other CYP11A1 targeting candidates, following a mutual agreement with Orion Corporation. This pivotal deal marks a significant advancement in the treatment of prostate […]
Zynext Ventures USA LLC, the venture capital arm of Zydus Lifesciences, has made a significant investment in Promaxo Inc., a leading developer of portable low-field MRI systems and minimally invasive robotics based in the U.S. This strategic partnership aims to advance healthcare innovation, particularly in the field of prostate cancer diagnosis and treatment. Promaxo’s groundbreaking […]
Telix Pharmaceuticals Limited (ASX: TLX) has announced the successful completion of the CUPID Phase I dose escalation study of TLX592, marking a significant advancement in targeted alpha therapy (TAT) for prostate cancer. This milestone is especially noteworthy as TLX592 incorporates Telix’s proprietary RADmAb engineered antibody technology, promising a new era in cancer treatment efficacy and […]